Trials / Completed
CompletedNCT04195919
The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
A clinical study to investigate the pharmacokinetics/ pharmacodynamics and safety/tolerability of Evogliptin in hemodialysis patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evogliptin 5mg | Participants receive Single oral administration of Evogliptin 5mg on day1 |
| DRUG | Evogliptin 5mg | Period 1(1d,After hemodialysis) → Wash-out period → Period 2(15d,Before hemodialysis) Hemodialysis patients receive Single oral administration of Evogliptin 5mg on day1 and day15 With a 14-day washout period |
Timeline
- Start date
- 2020-07-10
- Primary completion
- 2021-05-24
- Completion
- 2021-05-24
- First posted
- 2019-12-12
- Last updated
- 2021-12-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04195919. Inclusion in this directory is not an endorsement.